MED'INN'Pharma
Created in 2017
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
483 483Activities
Technologies
Entity types
Location
4 Rue Charles Bried, 25000 Besançon, France
Besançon
France
Employees
Scale: 2-10
Estimated: 5
Engaged corporates
5
4 1Added in Motherbase
1 year, 4 months ago
biotech Value proposition
A clinic-ready biotech developing human cell-derived secretome drugs to cure inflammation-related pathologies
Med’Inn’Pharma (MIP) is a clinic-ready Biotech company that was founded in 2017 as a spin-off from the French blood bank establishment (EFS) and of the French National Institute of Health (INSERM). MIP is a pioneer in developing a new class disease modifying therapies dedicated to resolve pathologic inflammation in a wide range of degenerative diseases and conditions.
Our founders are world leaders in immunology and inflammation-resolution, and have developed a patent protected process to harness bioactive molecules from physiologically conditioned human cells into a stable biologic drug product. This will allow to ‘transplant’ a bioactive resolutome* emitted during normal inflammation-resolution phase to pathologic deregulated environments. Our innovative approach works by restoring a complex but physiologic inflammation-resolution network, reprograms durably macrophages, and ‘fine-tunes’ inflammation-driven degenerative disorders for repair and regeneration and with that durably restore tissue and immune functionality and homeostasis.
At MIP we are using our knowledge to revert inflammation to resolve under physiologic condition for the development of a new generation of human cell-derived therapeutics with truly disease modifying properties applicable to a wide range of degenerative disorders and diseases.
! let's tackle scleroderma - systemic sclerosis first, as well as rheumatoid arthritis resistant to biologics !
*secretome from cells undergoing inflammation-resolution
Immunology, Inflammation, Resolution, Ageing, Next generation biologic drugs, Curative, Complex drug for complex diseases, Innovation, Regeneration, Wound healing, Inflammation-resolution, and macrophage reprogrammingOriginal language
A clinic-ready biotech developing human cell-derived secretome drugs to cure inflammation-related pathologies
Med’Inn’Pharma (MIP) is a clinic-ready Biotech company that was founded in 2017 as a spin-off from the French blood bank establishment (EFS) and of the French National Institute of Health (INSERM). MIP is a pioneer in developing a new class disease modifying therapies dedicated to resolve pathologic inflammation in a wide range of degenerative diseases and conditions.
Our founders are world leaders in immunology and inflammation-resolution, and have developed a patent protected process to harness bioactive molecules from physiologically conditioned human cells into a stable biologic drug product. This will allow to ‘transplant’ a bioactive resolutome* emitted during normal inflammation-resolution phase to pathologic deregulated environments. Our innovative approach works by restoring a complex but physiologic inflammation-resolution network, reprograms durably macrophages, and ‘fine-tunes’ inflammation-driven degenerative disorders for repair and regeneration and with that durably restore tissue and immune functionality and homeostasis.
At MIP we are using our knowledge to revert inflammation to resolve under physiologic condition for the development of a new generation of human cell-derived therapeutics with truly disease modifying properties applicable to a wide range of degenerative disorders and diseases.
! let's tackle scleroderma - systemic sclerosis first, as well as rheumatoid arthritis resistant to biologics !
*secretome from cells undergoing inflammation-resolution
Home - MedInnPharma
https://medinnpharma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Other 5 Dec 2024 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 2 Aug 2023 | | |
 PMT Public business cluster, French Cluster, Civic and Social Organizations | PMT Public business cluster, French Cluster, Civic and Social Organizations | Other 5 Dec 2024 | | |
 Linkera Consulting, Information Services | Linkera Consulting, Information Services | Other 9 Jun 2023 | | |
 Le Village by CA Startup accelerator & VC, Business Consulting and Services | Le Village by CA Startup accelerator & VC, Business Consulting and Services | Other 13 Jun 2023 | | |